Acute Lymphoblastic Leukemia, Pediatric
34
13
15
12
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
5.9%
2 terminated out of 34 trials
85.7%
-0.8% vs benchmark
9%
3 trials in Phase 3/4
8%
1 of 12 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 12 completed trials
Clinical Trials (34)
Determining the Mechanisms of Loss of CAR T Cell Persistence
Brain MRF in Children, Adolescents and Young Adults With Acute Leukemia
Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
MRD Detection by NGS in Pediatric T-ALL
Low GI Diet in Children and Adolescents With ALL
CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies
Behavioral Parenting Skills as a Novel Target for Improving Pediatric Medication Adherence: Study 3
Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic Leukemia
Massage Impact on Sleep in Pediatric Oncology
Vaccine Immune Recovery After Leukemia
CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL
A Phase I Dose Finding Study of MB-CART2219.1
Biology and Benefits of Music Play and Stories for Kids/Parents During ALL Treatment
Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
CD-19 CAR-T Cell for Pediatric ALL or Lymphoma
A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of MSD-HSCT Using a TBI or TMLI Conditioning Regimen for Pediatric ALL
A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of Haplo-HSCT Using a TBI or TMLI Conditioning Regimen for Pediatric ALL
Virtual Reality During Lumbar Punctures in Acute Lymphoblastic Leukemia